22Mar

How Metabolomics Can Raise the Bar in Drug Development

March 22, 2022 Metabolon 22

An Interview with Metabolon Chief Scientific Officer Ranga Sarangarajan, Ph.D. So why has this recognized R&D leader now chosen to focus on metabolomics? We sat down with Ranga to get his take on this rapidly growing technology and the potential it holds to propel drug development.

06Jan

Overcoming the Limitations of Mass Spectrometry Across Datasets

January 6, 2022 Metabolon 54

Metabolon implemented solutions to overcome some of the limitations of MS-based metabolomics while maximizing longitudinal reproducibility. At Metabolon, we implemented solutions based on data normalization and quality control (QC) as critical data processing components to improve data quality and reduce the non-biological variation in the samples. These solutions allow us to overcome some of the limitations of MS-based metabolomics while maximizing longitudinal reproducibility.

06Dec

Bile acid quantification provides insight into the mechanism of action for the treatment of NASH

December 6, 2021 Metabolon 59

Previous studies have shown that elevated bile acid concentrations are associated with the presence and severity of liver disorders. Given the link between bile acids and metabolic regulation, there is growing interest in understanding how bile acid dysregulation may contribute to NASH pathogenesis and progression.

17Nov

Event: Microbiome Connect: Gut Therapeutics

November 17, 2021 MetabolonDesign 97

Microbiome Connect: Gut Therapeutics will bring you essential solutions to the array of challenges operating in the microbiome field. The event will facilitate your discussions, uniting academics, biotechs and other industry stakeholders to share their exclusive research and innovation. Hear from big pharma to understand what they look for in a partner.

01Sep

Metabolomics Drives Identification of Rare Disease Signatures and Diagnoses

September 1, 2021 Metabolon 54

Rare diseases represent a unique challenge in clinical medicine. These diseases signify that few people have these diseases and even fewer have a successful diagnosis. Rare diseases are classified in many categories, including metabolic diseases, rare cancers, autoimmune diseases, blood disorders, digestive diseases, endocrine system disorders, nervous system diseases, reproductive disorders, and musculoskeletal diseases.

03Aug

Uncovering the metabolic basis for population differences in the immune response to malaria.

August 3, 2021 Metabolon 90

Malaria is a global health epidemic, with an estimated 229 million cases per year resulting in over 400, 000 deaths with the majority of these deaths being in children under the age of 5. The vast majority of cases in sub-Saharan Africa are caused by the Plasmodium falciparum parasite and transmitted via mosquitos. There is currently no approved vaccine for malaria and antimalarial drug resistance is a growing concern. There is hope that a better understanding of the interactions of the parasite and host metabolism could yield better treatment options.

21Jul

New Hope for Rare Disease Treatments

July 21, 2021 Metabolon 74

The number of rare diseases identified increases with each passing year due to the advent of deeper genome sequencing for patients, characterization of metabolic pathways, and identification/stratification of patients that historically were thought to have other diseases. Metabolomics is uniquely situated to identify biomarkers of disease for numerous rare diseases because it can identify the small molecule profiles of individual patients and link the changes to specific genetic mutations.

20May

Evaluating Metabolite Stability of Blood Samples for Clinical Applications

May 20, 2021 Metabolon 63

Metabolon’s extensive work establishes criteria for evaluating metabolite stability in clinical metabolomic applications and provides guidelines for disqualifying unstable metabolites deriving from sample handling and processing in clinical metabolomic studies to ensure pre-analytical compliance.

28Apr

Metabolomics and Shotgun Metagenomics Reveal Evidence That Glyphosate Exposure Affects the Gut Microbiome

April 28, 2021 Metabolon 76

A multi-omics approach provides valuable insights for investigating complex areas of science to enhance our understanding while Metabolon’s platform delivers interpretive depth not possible elsewhere. Additionally, the profiling of multiple matrices allowed for analysis of both microbiome derived compounds as well as how those changes may be reflected systemically, giving the work a much broader impact.

27Apr

Metabolon’s Validation of Dried Blood Spot (DBS) Cards for Metabolomics Analysis

April 27, 2021 Metabolon 69

DBS is a valuable and convenient sampling option to drive metabolomics research forward. In this Q&A section, we asked Kelli Goodman, Staff Scientist at Metabolon, to address some of the common questions regarding the use of DBS samples for metabolomics analysis.